To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.7571138.
In the absence of head-to-head trials, this analysis aimed to provide a fair indirect comparison of the efficacy between blinatumomab and inotuzumab ozogamicin (InO), two treatments for adult patients with relapsed or refractory acute lymphoblastic leukemia (R/R ALL) who received no more than one prior salvage therapy, by adjusting for cross-trial differences.
Patient-level data from the Phase 3 blinatumomab trial TOWER and published aggregated data from the Phase 3 InO trial INO-VATE-ALL were used to conduct matching-adjusted indirect comparisons. Patients with 2+ prior salvage therapies from TOWER were excluded because such patients were not included in INO-VATE-ALL. To ensure balance in the remaining patients, baseline characteristics for the TOWER patients were weighted to match the average baseline characteristics in INO-VATE-ALL, including sex, age, race, performance status, bone marrow blast, previous salvage therapy, previous allogeneic transplantation, complete remission with complete hematologic recovery (CR) to most recent induction therapy, and duration of first remission. Overall survival (OS), including median and restricted mean survival time (RMST) at 12 and 20.7 months, and CR were estimated and compared.
A total of 310 patients in TOWER were included (blinatumomab, n = 203; standard of care chemotherapy, n = 107). After matching the listed baseline characteristics, the median OS was 9.3 months for blinatumomab and 7.7 months for InO (weighted log-rank test p = 0.4). The relative RMST at 12 months was 1.6 months longer for blinatumomab than for InO [95% CI (0.1, 3.2); p = 0.04]; at 20.7 months the RMST was not significantly different. The CR rates were similar [anchor-based difference = − 2.8%, 95% CI (− 17.5%, 11.9%); p = 0.71].
After adjusting for cross-trial differences, blinatumomab demonstrated a similar CR rate and potential OS benefit versus InO among adult patients with R/R ALL who received no more than one prior salvage therapy. Further studies are suggested to confirm this finding.
Jabbour EJ, Stefan Faderl, and Hagop M. Kantarjian. Adult acute lymphoblastic leukemia. Mayo Clinic Proce. 2005;80(11):1517–27.
European Medicines Agency. Public summary of opinion on orphan designation: Blinatumomab for the treatment of acute lymphoblastic leukemia. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2009/10/WC500005882.pdf. Accessed 19 Sep 2017.
Larson RA, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995;85(8):2025–37. PubMed
Linker C, Damon L, Ries C, Navarro W. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol. 2002;20(10):2464–71. CrossRef
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Acute Lymphoblastic Leukemia. 2018. 2018. https://www.nccn.org/professionals/physician_gls/pdf/all.pdf. Accessed 24 Apr 2018
United States Food and Drug Administration. Highlights of prescribing information- BLINCYTO. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125557s008lbl.pdf. Accessed 12 Apr 2018.
European Medicines Agency. Blincyto. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003731/WC500198229.pdf. Accessed 12 Apr 2017.
European Medicines Agency. Assessment report: Besponsa. 2018. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004119/WC500231263.pdf. Accessed 24 Apr 2018
Stelljes M, Su Y, Fahrbach K, Vandendries E, Page V, Onyekwere U, et al. Indirect treatment comparison of inotuzumab ozogamicin and blinatumomab for relapsed or refractory acute lymphoblastic leukemia. In: Presented at American Society of Hematology (ASH) annual meeting on December 9–12, 2017 at Atlanta, GA.
Kantarjian Hea. Inotuzumab ozogamicin vs standard of care in patients with relapsed/refractory acute lymphoblastic leukemia: long-term results of the phase 3 INO-VATE study. In: Presented at 59th American Society of Hematology (ASH) annual meeting on September 9–12, 2017 at Atlanta, GA.
United States Food and Drug Administration. Highlights of prescribing information: BESPONSA. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761040s000lbl.pdf. Accessed 12 Apr 12 2018.
Rowe JM. Prognostic factors in adult acute lymphoblastic leukaemia. Br J Haematol. 2010;150(4):389–405. PubMed
Decision Support Unit- National Institute for Healthcare Excellence (NICE). Methods for population-adjusted indirect comparisons in submissions to NICE. 2018. http://scharr.dept.shef.ac.uk/nicedsu/wp-content/uploads/sites/7/2017/05/Population-adjustment-TSD-FINAL.pdf. Accessed 24 Apr 2018
Thom H, Jugl S, Palaka E, Jawla S, editors. Matching adjusted indirect comparisons to assess comparative effectiveness of therapies: usage in scientific literature and health technology appraisals. In: ISPOR 21st Annual International Meeting 2016 May 2016; Washington DC.
Bowman KS. Estimator: method of moments. Encyclopedia of statistical sciences. Hoboken: Wiley; 1998. p. 2092–8.
Martinelli G, et al. Complete molecular and hematologic response in adult patients with relapsed/refractory (R/R) Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (ALL) following treatment with blinatumomab: results from a phase 2 single-arm, multicenter study (ALCANTRA). Blood. 2015;126(23):679.
- Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II